Metformin Down-regulates Endometrial Carcinoma Cell Secretion of IGF-1 and Expression of IGF-1R

Yu Zhang*, Meng-Xiong Li, Huan Wang, Zheng Zeng, Xiao-Mao Li*

Abstract

As metformin can inhibit endometrial carcinoma (EC) cell growth and the insulin growth factor (IGF) system is active in EC, the question of whether it can regulate endometrial carcinoma cell secretion of IGF-1 or expression of IGF-1 receptor (IGF-1R) is of interest. In this study, serum IGF-1 levels in EC patients were found to be comparable with that in the non EC patients (p>0.05). However, the IGF-1 level in the medium of cultured cells after treatment with metformin was decreased (p<0.05). IGF-1R was highly expressed in human endometrial carcinoma paraffin sections, but IGF-1R and phosphor-protein kinase B/protein kinase B (p-Akt/Akt) expression was down-regulated after metformin treatment (p<0.05). In summary, metformin can reduce the secretion of IGF-1 by Ishikawa and JEC EC cell lines and their expression of IGF-1R to deactivate downstream signaling involving the PI-3K/Akt pathway to inhibit endometrial carcinoma cell growth.

Keywords: Metformin - endometrial carcinoma - IGF-1, IGF-1R

Introduction

Endometrial cancer is a most common gynecologic malignant tumor and the fourth malignant tumor for women in developed country (Barakat et al., 2007). Risk factors for the development of this cancer include unopposed estrogen stimulation, obesity, and diabetes among others (Morrow et al., 1993; Bershtein, 2014). Growth factors are polypeptides that act by autocrine, paracrine, and endocrine pathways to regulate cell proliferation and death (Goustin et al., 1986; Liang K et al., 2014).

The major players in extracellular signal are growth factor receptors. The type-1 insulin-like growth factor receptor (IGF-1R) is one member of tyrosine protein kinase receptor family, which is important for the establishment of a malignant cell phenotype, cell metastasis, protection from apoptosis and enhancement of cell proliferation (Baserga, 1995; Morrison et al., 2002; Samani et al., 2004). In human endometrial carcinoma, levels of IGF-1R have been correlated with tumor progression through phosphatidylinositol-3-kinase/protein kinase B/the mammalian target of Rapamycin, PI-3K/Akt/mTOR and rat sarcoma/rapidly accelerated fibrosarcoma/extracellular regulated protein kinases (Ras/Raf/Erk) signaling pathways (Casamassima et al., 1998; Sachdev et al., 2004). High IGF-1R expression in endometrial carcinoma has also been found to be an important prognostic factor (Hirano et al., 2004), and our previous study testified the inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma (Shu et al., 2011). In addition, endometrial carcinoma cells can synthesize and secrete IGF-I and IGF-II, which can integrate with their IGF-1R membrane receptor system and thereby cause continuous proliferation of tumor cells (Pavelic et al., 2007).

Metformin is a biguanide, commonly used for treating type 2 diabetes mellitus, increases insulin sensitivity and improves glycemic control (Nathan., 2009; Nevadunsky et al., 2014). Research shows that metformin can reduce the risks of some kinds of cancers including endometrial carcinoma (Goodwin et al., 2008; Pollak., 2010) and inhibit endometrial carcinoma cells growth by the mechanism that metformin acts as adenosine monophosphate-activated protein kinase (AMPK) agonist to inhibit mTOR phosphorylation (Xie et al., 2011; Arian et al., 2013). Moreover, researchers think that metformin prevented lung cancer caused by smoking is based on metformin reducing IGF-1 and blood levels of insulin to suppress mTOR effect, while mTOR is a protein that promotes the growth of lung cancer cells (Leone et al., 2014).

Whether metformin can regulate endometrial carcinoma cells secreting IGF-1 or expressing IGF-1R remains unknown. To answer this question, we tested the serum IGF-1 level in endometrial carcinoma patients before surgery and the medium of cells culture after treated with metformin. We also tested the IGF-1R in the human endometrial carcinoma paraffin sections and the change of IGF-1R expression, the signal pathway in vitro.
Patients and blood samples
12 cases of newly diagnosed as EC by pathology were grouped in the endometrial carcinoma (EC) group, and 12 cases of diagnosed as myoma or benign tumor of ovary without endometrial diseases were grouped in the control group during March 2013 to December 2013 at the Third Affiliated Hospital of Sun Yat-sen University. The average age was (51±13.65) years in the EC group and (47±10.23) years in the control group without significant difference. Diabetes and hormone taken in the past three months were excluded in all the cases. All EC cases were diagnosed as adenocarcinoma with high differentiated (5 cases), middle differentiated (5 cases) and low differentiated (2 cases) at the stage after surgery. The morning fasting venous blood 5ml of all the patients collected before surgery were allowed to clot for 2 h at room temperature and centrifuged for 20 min at 1000 rpm. Serum was removed and stored at -20°C until assayed for the detection of IGF-1 value by ELISA. All patients provided written informed consent for participation in this study. The study protocol was approved by the Ethics Committees of the Third Affiliated Hospital of Sun Yat-sen University.

Human endometrium paraffin section
Human normal endometrium tissues and endometrial carcinoma tissues were obtained respectively from above patients. The tissues were paraffin-embedded, formalin-fixed and cut into 3μm sections for immunohistochemistry staining.

Endometrial carcinoma cell lines, chemicals and antibodies
Human endometrial carcinoma cell lines Ishikawa and JEC were provided by American Type Culture Collection (Manassas, USA). The cells were routinely cultured in Dulbecco’s modification of Eagle’s medium (Gibco, USA) supplied with 10% fetal calf serum (Hyclone, USA), at 37 °C in the humidified atmosphere of a 5% CO₂ incubation.
Metformin was obtained from Sigma (USA). Mouse/Rat IGF-1 Immunoassay was obtained from Quantikine (USA). IGF-1Rβ Antibody #3027, Akt Antibody #4691, and Phospho-Akt (Ser473)#4060 were obtained from Cell Signaling Technology (USA), GAPDH Antibody was obtained from Santa Cruz (USA).

Immunooassay for IGF-1
Patients serum stored at -20°C were assayed for the detection of IGF-1. Cells were cultured as above and allowed to proliferate until about 70-90% confluence. The serum containing medium was removed, cells were washed with PBS, and serum-free medium and 0mM or 10mM of Metformin were added. After 4 days, cells and medium was separated by centrifuging at 150g for 5 min. Protein degradation in the supernatant was prevented with protease inhibitors (0.2 mM phenylmethylsulfonyl fluoride, 1mM EDTA, and 0.5 mg/liter leupeptin). The conditioned medium was dialyzed overnight at 4°C using membrane tubing with a cutoff of 3500 molecular weight. Aliquots of dialyzed conditioned media were stored at -20°C until assayed.

The IGF-1 Immunoassay was operated to detect IGF-1 as described in the kit protocols.

Immunohistochemistry
Paraffin sections were incubated with IGF-1Rβ Antibody (1:100 dilution) according to the manufacturer’s instructions. Slides were examined with a Leica microscope, scanned using an Aperio ScanScope instrument, and analyzed in ImageScope viewing software.

MTT assay
For 3- (4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) viability assay, 2-3x10⁵ cells/well were plated in 96-well plates, cultured in the appropriate media, and viability was evaluated using MTT.

Colony assays
Fifty cells per well were plated on 96-well plates 24 h later, medium was replaced, and cells were incubated with chemicals at indicate concentration. Medium was replaced every day, and at day 14, the cells were fixed and stained using 0.5% crystal violet (Sigma).

Western blot analysis
Cells were harvested and total protein was extracted with RIPA buffer together with a protease inhibitor cocktail (Sigma). Lysates were resolved on 10% SDS-PAGE and immunoblotted with the indicated antibodies. Band intensities were quantified using ImageJ software.

Statistical analysis
The data were compared using the Student t test or analysis of variance (ANOVA), as appropriate. All tests were two-tailed, and p<0.05 was considered significant.

Results
Serum IGF-1 in endometrial carcinoma
Serum IGF-1 concentration was (159.88±102.32)ng/ml in the endometrial carcinoma (EC) group, and was (167.92±112.26)ng/ml in the control group. There was no significant difference between the two groups (p>0.05, Figure 1).

IGF-1R highly expressed in endometrial carcinoma tissue
IGF-1R expressed abundantly in normal endometrial glands epithelial cells and endometrial carcinoma tissue, and most highly expressed in endometrial carcinoma tissue than in normal endometrial glands epithelial cells (Figure 2).

Metformin inhibited endometrial carcinoma cells Ishikawa and JEC viability
Effects of different concentration metformin on endometrial carcinoma cells Ishikawa and JEC growth were determined by MTT assay. Ishikawa cells were treated with metformin as indicated concentrations. Metformin attenuated the growth of Ishikawa and JEC cells (*p<0.05, **p<0.01, Figure 3). And the clone assay
Metformin Down-regulates IGF-1 Secretion and IGF-1R Expression in Endometrial Cancer Cells

Metformin reduced IGF-1 concentration in culture medium and down-regulated the expression of IGF-1Rβ

Cells culture medium were collected and processed, and acid-alcohol was extracted to remove IGF-binding proteins as described under Materials and Methods, after which radioimmunoassays for IGF-1 were performed. The concentration of IGF-1 measured was lower in the group treated with 10mM of metformin than that in control group (*p<0.05, Figure 5A).

Also showed that clone numbers in the 10mM of metformin treated group was significantly less than that in the control group (*p<0.05, Figure 4).

Discussion

IGF-1 is a polypeptide of 70 amino acids, mainly synthesized by the liver, and local organizations such as endometrium also secrete IGF-1 through autocrine and paracrine. And human serum IGF-1 level decrease by age and change by the phase of endometrium (Zhou et al., 1994). Studies demonstrate that IGF-1 is associated with the cancer development, progress and prognosis (Creighton et al., 2008; Torng et al., 2008), but some studies show no change (Lukanov et al., 2008; Lacey et al., 2004; Weiderpass et al., 2003) or decrease (Gunter et al., 2008) of serum IGF-1 level in endometrial carcinoma cases. In our study, serum IGF-1 level in the EC group was also comparable to that in the control group (Figure 1). So, till now serum IGF-1 can not be the serum predictor for endometrial carcinoma.
for endometrial carcinoma. But IGF-1 can be produced by the uterus endometrial stromal cells, regulating cell proliferation and differentiation in autocrine and paracrine manner (Haining et al., 1991). Moreover, endometrial carcinoma cells can synthesize and secrete IGF-1 and IGF-II, which can integrate with their IGF-1R membrane receptor and cause continuous proliferation of the tumor cells (Pavelie et al., 2007; Sarkissyan et al., 2014). And we also verified that high expression of GLP-1R in the EC tissue than that in the normal endometrial tissue (Figure 2). So local high IGF-1 level around the endometrial carcinoma cells matching with high expression of IGF-1R will promotes EC growth.

The fact of that metformin can inhibit cancer cells growth in vitro is accepted wildly, and the mechanism is associated with that metformin acts as AMPK agonist to inhibit mTOR phosphorylation (Zhou et al., 2001; Shaw et al., 2005; Xu et al., 2014), and that metformin can reduce insulin/insulin like growth factor signaling and suppress the PI-3K/Akt/mTOR axis (Luo et al., 2010; Matin et al., 2010). Metformin inhibits EC cells growth just as the results of MTT assay and clones formation in our study. Next, we observed the IGF-1 level in the medium of cells culture, the change of IGF-1R expression and its download signal after treated with metformin to testify whether metformin regulates IGF-1 level around the EC cells and IGF-1R expression to inhibit EC cells growth.

Growth factors are polypeptides that act by autocrine, paracrine, and endocrine pathways to regulate cell proliferation and death (Goustin et al., 1986). When growth factors like epidermal growth factor (EGF), transforming growth factor-a (TGF-a), and IGF-1 binds to its specific receptor, an intracellular signal cascade is initiated, resulting in activation of gene transcription, protein synthesis and mitosis (Derynck et al., 1987). And studies show that these growth factors including IGF-1 are potentially important in the development of endometrial carcinoma (Lelle et al., 1993; Pearl et al., 1993). And IGF-1 is demonstrated in endometrial carcinoma cell lines by IGF-1 RIA (Eugenio et al., 1999). Our data show IGF-1 secreted by endometrial carcinoma cell lines of Ishikawa and JEC can be detected in the culture, and the concentration of IGF-1 was lower in the group treated with 10mM of Metformin than in the control group (Figure 5A). As we know Metformin acts as AMPK activator to decrease protein synthesis (Salani et al., 2014), and the production of IGF-1 may be included. The IGF-1R is composed of extracellular α subunit and intracellular β subunit, which covalent bonds forming tyrosine kinase receptor. Its activation induces the phosphorylation of downstream tyrosine residues and itself or transmits growth signal from extracellular to nucleus through PI-3K/Akt/mTOR and Ras/Raf/Erk pathways (Casamassima et al., 1998). In our study, we detected intracellular β subunit of IGF-1R by western blot, and the intracellularβ subunit of IGF-1R was significantly down-regulated when treated with 10mM of metformin than that with 0mM of metformin, resulting in lowering the ratio of p-AKT/AKT (P < 0.05, Figure 5B). Other studies has also shown that metformin decrease IGF-1R complex of trastuzumab- resistant breast cancer cells (Liu et al., 2011) and suggested that metformin disrupts crosstalk between insulin/IGF-1R and G protein-coupled receptors in pancreatic cancer cells (Kisfalvi et al., 2009; Rozengurt et al., 2010; Markowska et al., 2014).

In summary, metformin can reduce endometrial carcinoma cell lines of Ishikawa and JEC secreting IGF-1 and expressing IGF-1R to deactivate downstream signaling involving the PI-3K/Akt pathway to inhibit endometrial carcinoma cell growth. Further detailed analyses and clinical trials will be necessary to identify the specific molecular mechanisms, and to determine whether metformin would have similar effects in vivo. We will explore this mechanism in patients or models of endometrial carcinoma as well in next study.

Acknowledgements

The study was supported by Guangdong Province Natural Science Fund S2012010009317.

References

Arian ER, Pascale F, Anne TN, et al (2013). Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends in Pharmacological Sciences, 2, 126-35.
Baserga R (1995). The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res, 55, 249-52.
Barakat RR, Grisby PW, Sabbatini. Corpus: epithelial tumor (2007). In: Hoskin WJ, Perez CA, Young RC principles and practice of gynecologic oncology, 2rd. Lippincott Williams & Wilkins, Philadelphia, 919-99.
Bershtein LM (2014). Endometrial cancer, estrogens and metabolic syndrome: scenario becomes more complicated. Vopr Onkol, 3, 254-62.
Casanmassima A, Rozengurt E (1998). Insulin-like growth factor I stimulates tyrosine phosphorylation of p130 (Cas), focal adhesion kinase, and paxillin. Role of phosphatidylinositol 3’-kinase and formation of a p130 (Cas). Crk complex. J Biol Chem, 273, 26149-56.
Creighton CJ, Casa A, Lazard Z, et al (2008). Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis, J Clin Oncol, 25, 4078-85.
Derynck R, Goeddel DV, Ullrich A, et al (1987). Synthesis of messenger RNAs for transforming growth factors a and b and the epidermal growth factor receptor by human tumors. Cancer Res, 47, 707-12.
Eugenio M, Giuseppe L, Giuseppe V, et al (1999). Insulin-like growth factor-I expression in normal and diseased endometrium. Int J Cancer, 80, 188-93.
Gunter MJ, Hoover DR, Yu H, et al (2008). A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev, 4, 921-9.
Goustin AS, Leof EB, Shipley GD, et al (1986). Growth factors and cancer. Cancer Res, 46, 1015-29.
Goodwin PJ, Pritchard KI, Ennis M, et al (2008). Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer, 8, 501-5.
Haining RE, Schofield JP, Jones DS, et al (1991). Identification of mRNA for epidermal growth factor and transforming growth factor-alpha present in low copy number in human endometrium and decidua using reverse transcriptase-polymerase chain reaction. J Mol Endocrinol, 6, 207-14.
Hiran0 S, Ito N, Takahashi S, et al (2004). Clinical implications
of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. *Eur J Gynaecol Oncol*, **25**, 187-91.

Kisfalvi K, Eibl G, Sinnett-Smith J, et al (2009). Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. *Cancer Res*, **69**, 6539-45.

Lelli R, Talavera F, Gretz HG, et al (1993). Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. *Cancer*, **72**, 519-25.

Lukanov A, Zeleniuch-Jacquotte A, Lundin E, et al (2004). Preferential st c level of F C- peptide, IGF- 1, IGFBP- 1, - 2 and 3 and r isk o f endometrial cancer. *Int J Cancer*, **2**, 262-8.

Lacey JV Jr, Potischman N, Madigan MP, et al (2004). Common genetic variation within IGF1, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. *Cancer Epidemiol Biomarkers Prev*, **4**, 607-12.

Luo Z, Zang M, Guo W (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. *Future Oncol*, **6**, 457-70.

Liu B, Fan Z, Edgerton SM, et al (2011). Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. *Cell Cycle*, **10**, 2959-66.

Leone A, Di Gennaro E, Bruzzese F, et al (2014). New perspective for an old antidiabetic drug: metformin as an anticancer agent. *Cancer Treat Res*, **159**, 355-76.

Liang K, Qiu S, Lu Y (2014). Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells. *Cancer Biol Ther*, **1**, 89-98.

Morrow CP, Curtin JP, Townsend DE (1993). Tumors of the endometrium, in Synopsis of Gynecologic Oncology, 4th ed., New York, NY: Churchill Livingstone, **209**.

Morrison KB, Tognon CE, Garnett MJ, et al (2002). ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. *Oncogene*, **21**, 5684-95.

Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, et al (2010). Metformin and cancer: Doses, mechanisms and the dandelion and hermetic phenomena. *Cell cycle*, **9**, 1057-64.

Markowska A, Pawalowska M, Filas V, et al (2014). Does Metformin affect ER, PR, IGF-1R, beta-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer? *Diabetol Metab Syndr*, **1**, 76.

Nathan DM, Buse JB, Davidson MB, et al (2009). Medical management of hyperglycemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy-A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia*, **52**, 17-30.

Nevadunsky NS, Van Arsdale A, Strickler HD, et al (2014). Metformin use and endometrial cancer survival. *Gynecol Oncol*, **1**, 236-40.

Pearl MP, Talavera F, Gretz HG, et al (1993). Mitogenic activity of growth factors in the human endometrial cancer cell lines HEC 1A and KLE. *Gynecol Oncol*, **49**, 325-32.

Pavelić Jasminka, Radaković Branko, Pavelić Krešimir (2007). Insulin-like growth factor -2 and its receptors (IGF-1R and IGF-2R / mannose-6-phosphate) in endometrial adenocarcinoma. *Gynecol Oncol*, **105**, 727-35.

Pollak M (2010). Metformin and other biguanides in oncology: advancing the research agenda. *Cancer Prev Res*, **3**, 1060-5.

Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010). Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. *Clin Cancer Res*, **16**, 2505-11.

Sachdev D, Hartell JS, Lee AV, et al (2004). A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. *J Biol Chem*, **279**, 5017-24.

Samani AA, Chevet E, Fulavollita L, et al (2004). Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of thetype 1 insulin-like growth factor receptor. *Cancer Res*, **64**, 3380-5.

Shaw RJ, Lamia KA, Vasquez D, et al (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science*, **310**, 1642-6.

Shu SR, Li XM, Yang YB, et al (2011). Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma. *International Immunopharmacology*, **2**, 244-9.

Salani B, Del Rio A, Marini C, et al (2014). Metformin, cancer and glucose metabolism. *Endocr Relat Cancer*, **6**, 461-71.

Sarkissyan S, Sarkissyan M, Wu Y, et al (2014). IGF-1 regulates Cyp61 induced breast cancer cell proliferation and invasion. *PloS One*, **7**, 103534.

Torg PL, LeeYC, Huang CY, et al (2008). Insulin- like growth factor protein-3 (IGFBP-3) act as an invasion- metastas is suppressor in ovarian endometrial carcinoma. *Oncogene*, **27**, 2137-47.

Weiderpass E, Brismar K, Bellocco R, et al (2003). Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. *Br J Cancer*, **9**, 1697-704.

Xie Y, Wang YL, Yu L, et al (2011). Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. *J Steroid Biochem Molec Biol*, **126**, 113-20.

Xu JN, Zeng C, Zhou Y, et al (2014). Metformin inhibits StAR expression in human endometriotic stromal cells via AMPK-mediated disruption of CREB-CRTC2 complex formation. *J Clin Endocrinol Metab*, **8**, 2795-803.

Zhou J, Dsupin BA, Giudice LC, Bondy CA (1994). Insulin-like growth factor system gene expression in human endometrium during the menstrual cycle. *J Clin Endocrinol Metab*, **79**, 1723-34.

Zhou G, Myers R, Li Y, et al (2001). Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest*, **108**, 1167-74.